Abstract: Hybridoma tumor cell line A.T.C.C. No. HB8116. An anti-H-Y antigen monoclonal antibody substance, "Hyclonalan," produced by said cell line. Use of Hyclonalan in immunoselection methodology.

Abstract: Method for isolating specific antibody hybridomas from a hybridoma cell mixture employing antigen-conjugated labeled microspheres and a label activated cell sorter. By selecting for labeled cells which produce light scatter and low red autofluorescence, viable single cells can be isolated and cloned which produce the desired antibodies.

Abstract: Method and kit for pregnancy detection adapted for self-performance. Urine to be tested is contacted with a lectin substrate being lectin bound to a solid support and capable of binding HCG. After separation of the lectin substrate from the urine the substrate is contacted with a liquid color reagent comprising a colored carrier material and anti-HCG antibodies bound thereto. If after separation of the colored reagent from the substrate the latter remains colored, the subject is pregnant, while lack of color indicates non-pregnancy. A preferred color reagent comprises killed and stained Staphylococci bacteria. There is also provided a kit for self-performance of the method comprising at least one column packed with a lectin substrate and adapted for the controlled passage of liquid therethrough, and a color reagent.

Abstract: A method of determining (1) the activity of complement, (2) the bacteriolytic activity of serum, or (3) the titer of antibody in a sample which comprises: (a) incubating complement-sensitive microorganisms containing an assayable intracellular component with the sample, and (b) detecting the assayable component released into the sample by lysis of the microorganisms.

Abstract: Method for discriminating unstained cells from stained cells in a heterogeneous population. Specified cell types are stained with an absorbing stain and all cells are passed through the class of flow cytometry instrumentation employing focused collimated light sources. Detection of low angle and wide angle light scatter permits differentiation between the cell types on the basis that cells stained with an absorbing stain produce comparatively less low angle light scatter and comparatively more wide angle light scatter than do unstained cells.

Abstract: A method for the determination of autoantibody in a test sample comprises contacting a substrate for the autoantibody with sample; treating the contacted substrate with labeled antihuman antibody selected from (1) a mixture comprising enzyme labeled antihuman antibody and fluorescent labeled antihuman antibody, and (2) antihuman antibody labeled with an enzyme and a fluorescent label; determining the enzyme activity of the treated substrate; and determining the immunofluorescent patterns in substrates exhibiting enzyme activity. The method is useful for the rapid screening and characterization of autoantibodies.

Abstract: "Two-site" or "sandwich" immunometric assay techniques for determination of the presence and/or concentration of antigenic substances in fluids using monoclonal antibodies are described and compared to conventional assays using polyclonal antibodies. Also described are inhibition assays using complexes of antigens with a monoclonal antibody.

Abstract: Microcapsules are sensitized with antibody to antigen of lymphocyte. Using such microcapsules, B cells and/or T cells can be selectively measured separately or simultaneously, in a simple manner, based on cell-mediated immunity which comprises applying the microcapsules sensitized with antibody to antigen of lymphocyte and sheep red cells or another kind of antibody-sensitized microcapsules that are optically distinguishable from the first antibody-sensitized microcapsules, to lymphocyte at the same time and thereafter independently measuring respective cells that are optically distinguishable from each other.The operation for the measurement is extremely simple and neither skill nor special equipment is required.

Abstract: Two-site immunometric assays for multideterminant antigens are described in which the antigen is reacted with an immobilized monoclonal antibody directed against one antigen determinant and a second monoclonal antibody that is directed against a distinct antigenic determinant and is of a different class or subclass than the immobilized monoclonal antibody. The second monoclonal antibody is labeled in direct versions of the assay and is reacted with a labeled antibody against it in indirect versions of the assay. The immobilizing medium and classes (subclasses) of the antibodies may be selected so as to reduce the likelihood of nonspecific binding enhance sensitivity and/or permit signal amplification.

Abstract: An HLA-DR typing test based on lymphocytotoxicity in which a vital dye-labeled total human lymphocyte sample, such as a sample of peripheral blood lymphocytes, is incubated with HLA-DR antisera, a monoclonal antibody against T cells, and complement and the DR type is determined based upon the resultant cytotoxicity as measured by the fluorescence of B cells surviving the incubation.

Abstract: A method for the detection and/or determination of an antigen having at least two separate antibody combining sites or antigenic determinants (i.e. a polyvalent antigen) using at least two different monoclonal antibodies which bind to the separate sites is described. In particular the method utilizes Protein A with a carrier to immobilize a first monoclonal antibody which in turn, can bind to one antigenic determinant on the antigen. The second antibody with a label is provided in a solution and binds to the second antigenic determinant on the antigen. A test kit is described for practicing the method. Novel anti-PGH synthase and anti-PGI.sub.2 synthase antibodies and hybridoma cells producing such antibodies are described.

Abstract: The use of colloidal gold as a bright field light microscopic marker for the immunocytochemical localization of antigens in histological sections, namely the two step or the bridge immuno gold staining method.

Abstract: The method assesses the level of general and specific cellular immunocompetence by measuring the responses of individuals to antigens in vitro employing the phenomenon of Leukocyte Migration Inhibition (LMI). The present invention differs from the previously described LMI technique in that antigens are individually incorporated into the agarose of assay plates, requiring no preincubation of antigens with patient blood cell (leukocyte) suspensions. The LMI assay method described herein is a practical alternative to delayed hypersensitivity skin testing to identify cellular immune deficiency and avoids the risk and inconvenience of the skin test procedure. The method also allows in vitro diagnosis of Tuberculosis and monitoring of tumor therapy.

Abstract: Method for detecting circulating immune complexes containing endogenously bound Clq. Capillary tubes are filled with a mixture of Clq coated GPO reagent cells, rabbit anti-Clq antibodies, and precipitate from the biological fluid sample containing immune complexes. The mixture is allowed to react and the tubes read for the presence or absence of agglutination indicative of the absence or presence of said immune complexes respectively.

Abstract: Methods for carrying the leucocyte adherence inhibition (LAI) assay for detecting the presence of cancer in responsive patients. One aspect of the invention utilizes incubation with agents which maximize the intracellular cycle 3',5'-adenosine monophosphate (cAMP) levels in the leucocytes as a means to expand the percentage of responding subjects in different cancers. A second aspect utilizes measurement of extracted, vital cell dye to avoid the need of counting the adhering or non-adhering leucocytes.

Abstract: In the course of a reaction in which one of the reactants is on the surface of carrier particles in a solution and another of the reactants is tagged with a fluorescent substance, some of the fluorescently tagged reactant attaches to, or is displaced from the carrier particle. The present invention relates to a method and device for determining the amount of fluorescently-tagged reactant which is attached to the carrier particle or which is free in solution, without physically separating the carrier particles from the solution. In a particular application of the invention (immunoassay) the reaction is between antibodies and antigens, and from the amount of fluorescently-tagged reactant which is attached to the carrier particle one can determine the unknown amount of antigen in a sample.

Abstract: A bright field light microscopic method for enumerating and characterizing subtypes of white blood cells and their precursors. The cells are labelled either directly or indirectly with gold-labelled antibodies in the presence of an inhibitor of oxidative phosphorylation.

Abstract: In the course of a reaction in which one of the reactants is on the surface of carrier particles in a solution and another of the reactants is tagged with a fluorescent substance, some of the fluorescently tagged reactant attaches to, or is displaced from the carrier particle. The present invention relates to a method and device for determining the amount of fluorescently-tagged reactant which is attached to the carrier particle or which is free in solution, without physically separating the carrier particles from the solution. In a particular application of the invention (immunoassay) the reaction is between antibodies and antigens, and from the amount of fluorescently-tagged reactant which is attached to the carrier particle one can determine the unknown amount of antigen in a sample.

Abstract: A novel method of diagnosis of atherosclerosis comprises comparing the migration of endothelial cells or of cells of endothelium-like morphology in vitro, in the presence of serum from the person being examined, with the migration of identical cells in the presence of serum from healthy persons or of other standard sera, and interpreting a reduced migration in the presence of serum of the person being examined as being an indication of the possible existance of atherosclerosis in this person. The cell migration is measured for example on monolayer cell cultures of pig aorta endothelial cells or of Balb/c 3T3-A31 cells, in which cultures a portion of the cellular layer has been removed. An outfit for carrying out the method contains the materials and devices necessary for the purpose.

Abstract: A method for detecting weakly expressed cell membrane antigens or antibodies thereto which involves contacting cells to be tested with a lipoprotein substance substantially free of heteroagglutins and isoagglutins, containing cholesterol and phospholipid. The lipoprotein substance is obtained from animal plasma.

Abstract: A stabilized radioimmunoassay product consisting of an antibody protein-bound to the cell wall of a selected bacterium whereby the antibody is irreversibly bound to the protein and remains specific for the antigen against which it was developed. The radioimmunoassay product is also characterized by the fact that the resultant complete product includes a phase of serum protein treatment to isolate the protein sites or other sites of nonspecific reactivity with the labelled antigen such that the non-specific binding of labelled antigen is significantly reduced. Also within the contemplation of the invention is the method of manufacturing the radioimmunoassay product which includes the initial phase of protein binding of the antibody to the selected bacterium and the subsequent serum treatment to isolate previously unutilized protein sites such that when said sites are subsequently exposed to labelled antigen it will be rejected.

Abstract: The sensitivity of hemagglutination inhibition tests is improved by introducing a determined amount of lyophilized antigen or antibody into serological tubes in the absence of the indicator component. The test fluid to be analyzed is incubated solely in the presence of its binding partner in a liquid phase. After completion of the binding reaction (about 5 hours but extendable to 18 hours), the sensitized indicator solid phase, usually consisting of sensitized red blood cells, is added. By this process a 10 to 20 fold increase in sensitivity of the hemagglutination inhibition test is routinely achieved.